Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2241 - Subcutaneous trastuzumab (H SC) with intravenous pertuzumab (P IV) and docetaxel (D IV) in HER2-positive advanced breast cancer (BC): MetaPHER second interim analysis

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Immunotherapy

Tumour Site

Breast Cancer

Presenters

Sherko Kümmel

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

S. Kümmel1, C.A. Tondini2, J. Abraham3, Z.I. Nowecki4, B. Itrych5, E. Hitre6, B. Karaszewska7, A. Juarez8, F. Morales-Vásquez9, J.M. Pérez García10, S. Cardona-Huerta11, D. Heinzmann12, J. He13, A.N. Duc12, A. Crepelle-Fléchais12, M. Martín14

Author affiliations

  • 1 Breast Unit, Kliniken Essen-Mitte, 45136 - Essen/DE
  • 2 Department Of Onco-hematology, ASST Papa Giovanni XXIII, Bergamo/IT
  • 3 Department Of Clinical Oncology, Velindre Cancer Centre, Cardiff/GB
  • 4 Centrum Onkologii-instytut, Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Warsaw/PL
  • 5 Department Of Oncology, Magodent, Warsaw/PL
  • 6 Department Of Medical Oncology And Clinical Pharmacology "b", National Institute of Oncology, Budapest/HU
  • 7 Przychodnia Lekarska, KOMED, Konin/PL
  • 8 Medical Oncology, CME Consultorio De Medicina Especializada, Mexico City/MX
  • 9 Fucam, Instituto Nacional de Cancerologia de Mexico, Mexico City/MX
  • 10 Medical Oncology, Hospital Universitari Vall d'Hebron, Barcelona/ES
  • 11 Centro De Cancer De Mama, Hospital Zambrano-Helion, Tecnológico de Monterrey, Monterrey/MX
  • 12 Global Product Development, F. Hoffmann-La Roche Ltd, Basel/CH
  • 13 Global Product Development, Genentech, Inc., South San Francisco/US
  • 14 Instituto De Investigación Sanitaria Gregorio Marañón, Ciberonc, Geicam, Universidad Complutense, Madrid/ES
More

Resources

Abstract 2241

Background

H SC (Herceptin® SC) was approved based on the HannaH study (Ismael Lancet Oncol 2012). The single-arm, open-label MetaPHER study (NCT02402712) is the first large Phase IIIb study to evaluate the safety and tolerability of H SC + P IV (PERJETA®) + D IV as first-line treatment in patients (pts) with HER2-positive metastatic/locally advanced BC. Here, we report interim safety and preliminary efficacy.

Methods

Pts are ≥18-year-old females whose disease was not previously treated with systemic non-hormonal anticancer therapy. Pts receive 600 mg fixed-dose H SC q3w + 840 mg loading/420 mg maintenance P IV q3w + ≥6 cycles D IV q3w (>6 at investigator’s discretion; 75 mg/m2 initial dose) until disease progression (PD), unacceptable toxicity, withdrawal of consent, death or predefined study end. The primary endpoint is overall and cardiac safety and tolerability. Adverse events (AEs) are graded per NCI–CTCAE v4.0.

Results

Of 418 enrolled pts, 412 started study treatment; 330 (196 on treatment, 134 in follow-up [FU]) were on study by data cutoff (5 Jan 18). Median FU duration was 16.3 months. In the safety population 406/412 pts (98.5%) experienced ≥1 any-grade AE; 213 (51.7%) grade ≥3 AEs; 101 (24.5%) serious AEs (SAEs); and 86 (20.9%) AEs leading to P IV, H SC or D IV discontinuation. 47 pts (11.4%) died: 38 (9.2%) due to PD; 9 (2.2%) due to AEs; none from cardiac death. AEs of interest included grade ≥3 cardiac AEs (3 pts; 0.7%); ejection fraction decrease to < 50% and ≥10% points from baseline (32; 7.8%); investigator-reported administration-related and local injection-site reactions (80; 19.4%, including 19 [4.6%] with an AE related to H SC only). No MedDRA-preferred-term congestive heart failure was reported. 249/336 pts with baseline measurable disease had an objective response (74.1% [95% CI 69.1–78.7]). The clinical benefit rate was 81.1% (334/412 pts [95% CI 77.3–84.9]). 1-year progression-free survival was 63.1% (95% CI 58.4–68.2).

Conclusions

Safety and efficacy profiles of H SC + P IV as first-line treatment for pts with HER2-positive advanced BC were consistent with the known profiles for the H IV + P IV combination, and no new safety signals identified. The final analysis is planned for 2019.

Clinical trial identification

NCT02402712.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Editorial Acknowledgement

Support for third-party writing assistance for this abstract, furnished by Helen Keyworth, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Disclosure

S. Kümmel: Honoraria: Roche, Celgene, Novartis, Amgen and Daiichi Sankyo; Consultant/advisor: Roche; Travel/accommodations/expenses: Roche and Celgene. C.A. Tondini: Consultant/advisor: Myriad Genetics; Speakers’ bureau: Amgen; Travel/accommodations/expenses: Roche/Genentech, Novartis and Celgene. J. Abraham: Honoraria, including travel expenses for advisory roles: Novartis and Genomic Health. Z.I. Nowecki: Travel/accommodations/expenses: Roche/Genentech, Novartis and Amgen. A. Juarez: Honoraria, support for national and international congresses and clinical trials: Roche. F. Morales-Vásquez: Honoraria, educational grants and Speakers’ bureaus: Roche, AstraZeneca, Pfizer, MSD, Novartis, Teva and Eli Lilly. S. Cardona-Huerta: Honoraria for advisory and consulting/speaker roles: Roche. D. Heinzmann: Employee: F. Hoffmann-La Roche; Shares: Roche. J. He: Employee: F. Hoffmann-La Roche. A.N. Duc, A. Crepelle-Fléchais: Employee: F. Hoffmann-La Roche. M. Martín: Honoraria: Roche, Genentech, Novartis, Lilly and AstraZeneca; Research grants: Roche and Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.